الفهرس 
ACUTE LYMPHOBLASTIC LEUKEMIAOnly 14 pages are availabe for public view
 |  | from | 187 |  |  |
| | | from | 187 | | |
Abstract
T
his study was conducted to assess expression of IL-15 level in adult Egyptian acute leukemia patients, its correlation with disease free survival, overall survival and relapse rate, as well as its possible correlation with other prognostic parameters.
Serum IL-15 was much higher in patients with ALL than the control subjects (P = 0.015).
ALL patients with high risk cytogenetics had lower serum IL-15 level compared to those with non-high risk cytogenetics (P = 0.047).
No correlation could be found between serum IL-15 level and total leucocytic count, risk stratification in patients with ALL (P = 0.572) and (P = 0.411) respectively.
ALL patients with high serum IL-15 level achieved 1st complete response (CR) less than those with low or average serum IL-15 level (P = 0.038).
ALL patients with high serum IL-15 level achieved minimal residual disease (MRD) negativity less than those with low or average serum IL-15 level (P = 0.006).
No correlation could be found between serum IL-15 level and relapse rate in patients with ALL (P = 0.157).
ALL Patients with high serum IL-15 level had shorter survival compared to those with low or average serum IL-15 level (P = 0.005).
The optimal cut-off value for serum IL-15 in predicting patient survival in patients with ALL was 200ng/L.
No correlation could be found between serum IL-15 level and date of death, LDH level or percentage of blasts cell in bone marrow in patients with ALL (P = 0.221), (P = 0.696) and (P = 0.185) respectively.
Serum IL-15 was much higher in patients with AML than the control subjects (P = 0.010).
No correlation could be found between serum IL-15 level and total leucocytic count or high risk cytogenetics in patients with AML (P = 0.533) and (P = 0.146) respectively.
AML patients with high risk features had higher serum IL-15 level compared to those with low or intermediate risk features (P = 0.048).
AML patients with high serum IL-15 level achieved 1st complete response (CR) less than those with average serum IL-15 level (P = 0.015).
AML patients with high serum IL-15 level achieved minimal residual disease (MRD) negativity less than those with average serum IL-15 level (P = 0.002).
No correlation could be found between serum IL-15 level and relapse rate in patients with AML by (P = 0.505).
AML patients with high serum IL-15 level had shorter survival compared to those with low or average serum IL-15 level (P<0.001).
The optimal cut-off value for serum IL-15 in predicting patient survival in patients with AML was 190 ng/L.
There was no statistically significant difference between patients with ALL and AML as regard serum IL-15 level (P = 0.876).
There was no statistically significant correlation between serum IL-15 level and serum LDH level or percentage of blasts cell in bone marrow in patients with AML (P = 0.731) and (P = 0.111) respectively.
Serum IL-15 level had negative correlation with the date of death in patients with AML (P = 0.001).